GCP
RCKT icon

Gill Capital Partners’s Rocket Pharmaceuticals RCKT Stock Holding History

Gill Capital Partners’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14 Buy
+4
New +$16 ﹤0.01% 695

Other funds holding RCKT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Gill Capital Partners's RCKT Position: Q1 2026 in Review

Gill Capital Partners opened a new position in Rocket Pharmaceuticals (RCKT) in Q1 2026: 4 shares worth $14. The stake represents ﹤0.01% of the portfolio and ranks #695 among its holdings.

198 funds tracked by Wall St. Rank hold RCKT as of Q1 2026.

  • Gill Capital Partners held 4 shares of Rocket Pharmaceuticals worth $14 as of Q1 2026.
  • Rocket Pharmaceuticals was a new Gill Capital Partners position in Q1 2026.
  • Rocket Pharmaceuticals made up ﹤0.01% of Gill Capital Partners's portfolio in Q1 2026, its #695 holding.
  • 198 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q1 2026.

Based on Gill Capital Partners's 13F filing for Q1 2026, filed 13 Apr 2026.